US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus U.S. Dividend ETF

30.29

+0.26610.89%

Post-market: 30.290.00000.00%16:10 EDT

Volume:207

Turnover:6K

Market Cap:17.42M

PE:- -

High:30.35

Open:30.35

Low:30.29

Close:30.03

52wk High:30.69

52wk Low:24.79

Shares:575.00K

Float Shares:575.00K

Volume Ratio:1.77

T/O Rate:0.04%

Dividend:0.38

Dividend Rate:1.27%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/VUS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","market":"US","secType":"STK","nameCN":"Virtus U.S. Dividend ETF","latestPrice":30.2921,"timestamp":1789156800000,"preClose":30.026,"halted":0,"volume":207,"hourTrading":{"tag":"盘后","latestPrice":30.2921,"preClose":30.2921,"latestTime":"16:10 EDT","volume":6,"amount":181.7526,"timestamp":1789157404968,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008862319323253232,"floatShares":575004,"shares":575004,"eps":0,"marketStatus":"Post-Mkt","change":0.2661,"latestTime":"09-11 19:45:27 EDT","open":30.35,"high":30.35,"low":30.2921,"amount":6301,"amplitude":0.001928,"askPrice":45.48,"askSize":200,"bidPrice":15.16,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":30.026,"sharesOutstanding":625004,"nav":30.198,"aum":17364108.34,"dividendRate":0.012667,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.2921,"preClose":30.2921,"latestTime":"16:10 EDT","volume":6,"amount":181.7526,"timestamp":1789157404968,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.766211},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","floatShares":575004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.766211,"shares":575004,"dividePrice":0.3837,"high":30.35,"amplitude":0.001928,"preClose":30.026,"low":30.2921,"week52Low":24.79,"pbRate":"--","week52High":30.6924,"institutionHeld":0,"latestPrice":30.2921,"eps":0,"divideRate":0.012667,"volume":207,"delay":0,"ttmEps":0,"open":30.35,"prevYearClose":25.2797,"prevWeekClose":30.5521,"prevMonthClose":30.2009,"prevQuarterClose":29.8174,"fiveDayClose":30.4704,"twentyDayClose":30.6042,"sixtyDayClose":30.1104},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VUS\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"VUS","amount":0.164,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-29","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-29"},{"date":"2026-03-20","symbol":"VUS","amount":0.2199,"announcedDate":"2026-03-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VUS\",market:\"US\",,,undefined,":[{"executeDate":"2026-03-20","recordDate":"2026-03-20","paymentDate":"2026-03-27","value":0.2199,"currency":"USD"},{"executeDate":"2026-06-22","recordDate":"2026-06-22","paymentDate":"2026-06-29","value":0.164,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VUS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VUS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666530593","title":"Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530593?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:00","pubTimestamp":1789041600,"startTime":"0","endTime":"0","summary":"-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359459/0/en/rhythm-pharmaceuticals-announces-new-data-presentations-at-the-european-society-for-paediatric-endocrinology-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VAI","EPV","BK4166","VUS","AVP","EC","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627957","title":"Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627957","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627957?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --  BOSTON, Aug.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349657/0/en/rhythm-pharmaceuticals-announces-mhlw-approval-of-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity-ho-in-japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4157","VUS","AVP","BK4201","BMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848797","title":"Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848797","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848797?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968000,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346041/0/en/rhythm-pharmaceuticals-announces-appointment-of-manher-aj-joshi-as-chief-medical-officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","EC","BK4534","BK4566","NKE","STYL","LU0310800379.SGD","LU0889566641.SGD","LU0786609619.USD","LU1267930227.SGD","LU1267930813.SGD","VUS","LU0128525929.USD","BK4588","LU0310800965.SGD","LU0029864427.USD","BK4585","BK4561","LU1267930573.SGD","LU1303367103.USD","BK4558","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","LU0792757196.USD","LU0823411888.USD","LU2098885051.SGD","LU0052756011.USD","BK4146","BK4581","BK4201","LU0708994859.HKD","AVP","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658902819","title":"Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658902819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658902819?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --BOSTON, Aug.  11, 2026  (GLOBE NEWSWIRE) -- Rhythm Phar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342640/0/en/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-in-the-united-kingdom-for-treatment-of-obesity-and-control-of-hunger-in-patients-w.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","BK4157","EC","BMI","AVP","BK4211","UBCP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657859567","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2657859567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657859567?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  04, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338772/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","BK4201","VUS","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558874","title":"Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558874?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:01","pubTimestamp":1785841260,"startTime":"0","endTime":"0","summary":"-- U.S. launch of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 n","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338168/0/en/Rhythm-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574139.USD","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","LU2237443622.USD","LU1363072403.SGD","VUS","LU2237443895.HKD","CMC","IE00BFXG1179.USD","IE00BHPRN162.USD","LU2237443978.SGD","BK4006","EC","LU2237443549.SGD","LU2237443465.HKD","PWS","IE00BZ1G4Q59.USD","LU2746668461.USD","BK4201","LU0149725797.USD","LU0267386448.USD","LU2237443382.USD","LU0971096721.USD","LU2746668974.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558369","title":"Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558369","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558369?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:55","pubTimestamp":1785840900,"startTime":"0","endTime":"0","summary":"-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338126/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Data-from-Phase-2-Trial-that-Showed-RM-718-Demonstrated-Positive-Efficacy-Signal-in-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4166","EC","BK4201","AVP","RM","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653927705","title":"Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653927705?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"BOSTON, July  21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330408/0/en/Rhythm-Pharmaceuticals-to-Report-Second-Quarter-2026-Financial-Results-on-Tuesday-August-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","EC","AVP","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650919584","title":"Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2650919584","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650919584?lang=en_us&edition=fundamental","pubTime":"2026-07-09 05:07","pubTimestamp":1783544820,"startTime":"0","endTime":"0","summary":"BOSTON, July  08, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324480/0/en/Rhythm-Pharmaceuticals-Announces-The-New-England-Journal-of-Medicine-Publication-of-Phase-3-TRANSCEND-Trial-Results-in-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","EC","BMI","EMA","BK4201","BK4081","CHMP","BK4157","AVP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785500","title":"Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785500","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785500?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553660,"startTime":"0","endTime":"0","summary":"-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years --  -- Bivamelagon therapy achieved progressive reductions in BMI a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3312120/0/en/Rhythm-Pharmaceuticals-Announces-Multiple-New-Data-Presentations-from-MC4R-Agonists-in-Acquired-Hypothalamic-Obesity-HO-Bardet-Biedl-Syndrome-BBS-and-Prader-Willi-Syndrome-PWS-at-E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ENDO","BK4201","VUS","EC","AVP","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643185082","title":"Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643185082","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643185082?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:01","pubTimestamp":1781294460,"startTime":"0","endTime":"0","summary":"BOSTON, June  12, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/12/3311304/0/en/Rhythm-Pharmaceuticals-to-Announce-Interim-Six-Month-Phase-2-Results-Evaluating-Setmelanotide-in-Patients-with-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","VUS","AVP","EC","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640488519","title":"Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2640488519","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640488519?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":" 18F-GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg , as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image.  18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs , the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head , spine , heart , and pelvis . Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305065/0/en/Lantheus-LNTH-2513-18F-GP1-PET-CT-Awarded-SNMMI-s-Image-of-the-Year.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0498741114.HKD","IE00BMG7P702.HKD","LNTH","LU0170899867.USD","LU2462157665.USD","LU0072461881.USD","IE00BD4GTW91.USD","LU0496367417.USD","LU1244550221.USD","LU0345780950.USD","BK4198","BK4559","IE00BD4GTT62.SGD","LU2360032135.SGD","LU0654597011.USD","LU1791807156.HKD","LU2236285917.USD","LU0128525689.USD","VUS","BU","BK4161","LU1543694498.USD","LU0345780521.USD","LU0498741890.SGD","LU2413666699.HKD","LU0106831901.USD","SG9999001143.SGD","LU1668664300.SGD","LU1162221912.USD","LU0612318971.USD","LU1430597077.USD","LU0345781412.USD","BK4585","IE00BZ18W340.USD","LU0320765646.SGD","IE00BMG7P819.SGD","CUL3","BK4208","LU0203345920.USD","LU0203347892.USD","LU1023059493.AUD","LU1201861249.SGD","D","A","IE00BSNM7G36.USD","E","BK4207","IE00BN0W2V16.EUR","B","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639862225","title":"Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639862225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639862225?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:00","pubTimestamp":1780056000,"startTime":"0","endTime":"0","summary":"BOSTON, May  29, 2026  (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303535/0/en/Rhythm-Pharmaceuticals-Announces-Seven-Abstracts-Accepted-for-Presentation-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","PWS","AVP","BK4183","BK4201","ENDO","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698175","title":"Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698175","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698175?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"BOSTON, May  28, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302763/0/en/Rhythm-Pharmaceuticals-Announces-Publication-of-New-Bardet-Biedl-Syndrome-Diagnostic-Algorithm-in-the-American-Journal-of-Medical-Genetics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","VUS","BK4183","BK4117","BK4201","BK4107","ENDO","EC","AVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514825","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514825","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514825?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"BOSTON, May  26, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300998/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","EC","VUS","AVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219760","title":"Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219760?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses demonstra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292752/0/en/Rhythm-Pharmaceuticals-Announces-New-Data-Presentations-at-the-2026-European-Congress-of-Endocrinology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","BK4585","AVP","EC","LU1261432733.SGD","VUS","CP","EPV","LU1989763427.SGD","BK4016","LU1989763690.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633013363","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633013363","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633013363?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"BOSTON, May  06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288752/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Bank-of-America-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","LU0208291251.USD","LU0306807586.USD","BK4201","LU0256863811.USD","VUS","LU1496350502.SGD","BK4534","LU0130103400.USD","LU0149725797.USD","IE00BLSP4452.SGD","BAC","LU0648001328.SGD","PGF","AVP","LU0640476718.USD","LU2129689514.USD","LU1883839398.USD","LU1069347547.HKD","BK4207","IE0034235188.USD","LU0052756011.USD","LU0211331839.USD","LU1804176565.USD","LU0787776722.HKD","LU0310800965.SGD","LU1668664300.SGD","LU0128525689.USD","LU0128526141.USD","LU1880398471.USD","LU2129689431.USD","LU1363072403.SGD","LU1894683348.USD","LU1162221912.USD","EC","LU0234572021.USD","IE00BLSP4239.USD","LU0053666078.USD","LU0417517546.SGD","LABU","LU0321505439.SGD","XBI","LU2265009873.SGD","LU0477156797.USD","LU0234570918.USD","IE0002270589.USD","LU0130102774.USD","LU0477156953.USD","LU0314106906.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633140419","title":"Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633140419","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633140419?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"-- IMCIVREE (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- Fir","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287506/0/en/Rhythm-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","EC","CHMP","BK4201","PWS","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958408","title":"Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958408","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958408?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:00","pubTimestamp":1777896000,"startTime":"0","endTime":"0","summary":"-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy ---- Weight category improvements observed in pedia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286656/0/en/Rhythm-Pharmaceuticals-Announces-New-Data-Presentations-in-Acquired-Hypothalamic-Obesity-at-Pediatric-Endocrine-Society.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","AVP","EC","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632861999","title":"Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2632861999","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632861999?lang=en_us&edition=fundamental","pubTime":"2026-05-01 18:55","pubTimestamp":1777632900,"startTime":"0","endTime":"0","summary":"-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285813/0/en/Rhythm-Pharmaceuticals-Announces-IMCIVREE-Setmelanotide-Granted-Marketing-Authorization-by-European-Commission-for-the-Treatment-of-Obesity-and-Control-of-Hunger-in-Patients-with-A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","BK4201","BMI","BK4157","EC","VUS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}